Yeah basically the MACs (the organisations responsible for...

Yeah basically the MACs (the organisations responsible for implementing LCDs) are going through a process to revise the current LCD. They have proposed a new LCD that removes coverage for our procedure, but it is unlikely to be implemented given they fail to consider a substantial amount of evidence, and considering the considerable backlash they've received.

As a precedent example, the MACs attempted to implement an LCD back in 2020 to remove coverage for canaloplasty but that also received significant backlash, and was subsequently retired. Even if the LCD is implemented though, there is an appeals process (which another ASX company, PEB, has been successful in undertaking)

Regardless of the low probability of this LCD actually impacting EYE's financials, it will certainly continue to act as a drag on the share price. On the other hand, there's now a high probability catalyst for a rerate if/when we get the news that the LCD has been dropped